Cargando…

Hemoglobin glycation index as a useful predictor of therapeutic responses to dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes

INTRODUCTION: A high hemoglobin glycation index (HGI) and glycated hemoglobin (HbA1c) level are associated with greater inflammatory status, and dipeptidyl peptidase-4 (DPP-4) inhibitors can suppress inflammation. We aimed to evaluate the relationship between HGI and the therapeutic effect of DPP-4...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yu-Wei, Wang, Jun-Sing, Sheu, Wayne H-H, Lin, Shih-Yi, Lee, I-Te, Song, Yuh-Min, Fu, Chia-Po, Lee, Chia-Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5300176/
https://www.ncbi.nlm.nih.gov/pubmed/28182722
http://dx.doi.org/10.1371/journal.pone.0171753
_version_ 1782506140164161536
author Chen, Yu-Wei
Wang, Jun-Sing
Sheu, Wayne H-H
Lin, Shih-Yi
Lee, I-Te
Song, Yuh-Min
Fu, Chia-Po
Lee, Chia-Lin
author_facet Chen, Yu-Wei
Wang, Jun-Sing
Sheu, Wayne H-H
Lin, Shih-Yi
Lee, I-Te
Song, Yuh-Min
Fu, Chia-Po
Lee, Chia-Lin
author_sort Chen, Yu-Wei
collection PubMed
description INTRODUCTION: A high hemoglobin glycation index (HGI) and glycated hemoglobin (HbA1c) level are associated with greater inflammatory status, and dipeptidyl peptidase-4 (DPP-4) inhibitors can suppress inflammation. We aimed to evaluate the relationship between HGI and the therapeutic effect of DPP-4 inhibitors. METHODS: This retrospective cohort study followed 468 patients with type 2 diabetes receiving DPP-4 inhibitor treatment for 1 year. Estimated HbA1c was calculated using a linear regression equation derived from another 2969 randomly extracted patients with type 2 diabetes based on fasting plasma glucose (FPG) level. The subjects were divided into two groups based on HGI (HGI = observed HbA1c - estimated HbA1c). Mixed model repeated measures were used to compare the treatment efficacy after 1 year in patients with a low (HGI<0, n = 199) and high HGI (HGI≧0, n = 269). RESULTS: There were no significant group differences in mean changes of FPG after 1 year (-12.8 and -13.4 mg/dL in the low and high HGI groups, respectively). However, the patients with a high HGI had a significantly greater reduction in HbA1c from baseline compared to those with a low HGI (-1.9 versus -0.3% [-20.8 versus -3.3 mmol/mol]). Improvements in glycemic control were statistically significantly associated with the tested DPP-4 inhibitors in the high HGI group (-2.4, -1.4, -1.2 and -2.2% [-26.2, -15.3, -13.1 and -24.0 mmol/mol] for vildagliptin, linagliptin, saxagliptin and sitagliptin, respectively) but not in the low HGI group. CONCLUSIONS: The HGI index derived from FPG and HbA1c may be able to identify who will have a better response to DPP-4 inhibitors.
format Online
Article
Text
id pubmed-5300176
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-53001762017-02-28 Hemoglobin glycation index as a useful predictor of therapeutic responses to dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes Chen, Yu-Wei Wang, Jun-Sing Sheu, Wayne H-H Lin, Shih-Yi Lee, I-Te Song, Yuh-Min Fu, Chia-Po Lee, Chia-Lin PLoS One Research Article INTRODUCTION: A high hemoglobin glycation index (HGI) and glycated hemoglobin (HbA1c) level are associated with greater inflammatory status, and dipeptidyl peptidase-4 (DPP-4) inhibitors can suppress inflammation. We aimed to evaluate the relationship between HGI and the therapeutic effect of DPP-4 inhibitors. METHODS: This retrospective cohort study followed 468 patients with type 2 diabetes receiving DPP-4 inhibitor treatment for 1 year. Estimated HbA1c was calculated using a linear regression equation derived from another 2969 randomly extracted patients with type 2 diabetes based on fasting plasma glucose (FPG) level. The subjects were divided into two groups based on HGI (HGI = observed HbA1c - estimated HbA1c). Mixed model repeated measures were used to compare the treatment efficacy after 1 year in patients with a low (HGI<0, n = 199) and high HGI (HGI≧0, n = 269). RESULTS: There were no significant group differences in mean changes of FPG after 1 year (-12.8 and -13.4 mg/dL in the low and high HGI groups, respectively). However, the patients with a high HGI had a significantly greater reduction in HbA1c from baseline compared to those with a low HGI (-1.9 versus -0.3% [-20.8 versus -3.3 mmol/mol]). Improvements in glycemic control were statistically significantly associated with the tested DPP-4 inhibitors in the high HGI group (-2.4, -1.4, -1.2 and -2.2% [-26.2, -15.3, -13.1 and -24.0 mmol/mol] for vildagliptin, linagliptin, saxagliptin and sitagliptin, respectively) but not in the low HGI group. CONCLUSIONS: The HGI index derived from FPG and HbA1c may be able to identify who will have a better response to DPP-4 inhibitors. Public Library of Science 2017-02-09 /pmc/articles/PMC5300176/ /pubmed/28182722 http://dx.doi.org/10.1371/journal.pone.0171753 Text en © 2017 Chen et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Chen, Yu-Wei
Wang, Jun-Sing
Sheu, Wayne H-H
Lin, Shih-Yi
Lee, I-Te
Song, Yuh-Min
Fu, Chia-Po
Lee, Chia-Lin
Hemoglobin glycation index as a useful predictor of therapeutic responses to dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes
title Hemoglobin glycation index as a useful predictor of therapeutic responses to dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes
title_full Hemoglobin glycation index as a useful predictor of therapeutic responses to dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes
title_fullStr Hemoglobin glycation index as a useful predictor of therapeutic responses to dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes
title_full_unstemmed Hemoglobin glycation index as a useful predictor of therapeutic responses to dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes
title_short Hemoglobin glycation index as a useful predictor of therapeutic responses to dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes
title_sort hemoglobin glycation index as a useful predictor of therapeutic responses to dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5300176/
https://www.ncbi.nlm.nih.gov/pubmed/28182722
http://dx.doi.org/10.1371/journal.pone.0171753
work_keys_str_mv AT chenyuwei hemoglobinglycationindexasausefulpredictoroftherapeuticresponsestodipeptidylpeptidase4inhibitorsinpatientswithtype2diabetes
AT wangjunsing hemoglobinglycationindexasausefulpredictoroftherapeuticresponsestodipeptidylpeptidase4inhibitorsinpatientswithtype2diabetes
AT sheuwaynehh hemoglobinglycationindexasausefulpredictoroftherapeuticresponsestodipeptidylpeptidase4inhibitorsinpatientswithtype2diabetes
AT linshihyi hemoglobinglycationindexasausefulpredictoroftherapeuticresponsestodipeptidylpeptidase4inhibitorsinpatientswithtype2diabetes
AT leeite hemoglobinglycationindexasausefulpredictoroftherapeuticresponsestodipeptidylpeptidase4inhibitorsinpatientswithtype2diabetes
AT songyuhmin hemoglobinglycationindexasausefulpredictoroftherapeuticresponsestodipeptidylpeptidase4inhibitorsinpatientswithtype2diabetes
AT fuchiapo hemoglobinglycationindexasausefulpredictoroftherapeuticresponsestodipeptidylpeptidase4inhibitorsinpatientswithtype2diabetes
AT leechialin hemoglobinglycationindexasausefulpredictoroftherapeuticresponsestodipeptidylpeptidase4inhibitorsinpatientswithtype2diabetes